Table 2.

Demographic characteristics of the participants receiving the second dose of COV2-vaccination (n = 301).

Qualitative variables		AstraZeneca		COVIran Barekat		Sinopharm		Total
		Frequency	Percentage	Frequency	Percentage	Frequency	Percentage	Frequency	Percentage
Sex	Female	40	42.1	48	45.7	48	47.5	136	45.2
	Male	55	57.9	57	54.3	53	52.5	165	54.8
	Total	95	100	105	100	101	100	301	100
Infection history	Negative	82	86.3	97	92.4	91	90.1	270	89.7
	Positive	13	13.7	8	7.6	10	9.9	31	10.3
	Total	95	100	105	100	101	100	301	100
		Median (IQR 25–75)
		AstraZeneca		COVIran Barekat		Sinopharm		Total
Age (year)		33 (26–40)		41(31.5–52)		40 (32–48)		38(30–48)

SD, standard deviation.